Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galenica Will Leverage Aspreva Acquisition To Strengthen Specialty Pharma Group

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss drug company seeks to buy Aspreva for roughly $915 million to accelerate development of its pharma arm.

You may also be interested in...

Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.

Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis

Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.

Daiichi Sankyo/Luitpold Submit Injectafer For Iron Deficiency Anemia

Firm is focusing the iron replacement therapy on the women’s health market, including heavy uterine bleeding and postpartum.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts